Mark Mcdade - 10 Jun 2022 Form 4 Insider Report for Icosavax, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2022, 16:12:30 UTC
Prior SEC filing: 13 Jun 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark McDade

Key filing fact

Mark Mcdade filed Form 4 for Icosavax, Inc. on 14 Jun 2022.

Key facts

This page summarizes Mark Mcdade's Form 4 filing for Icosavax, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2022, 16:12.

Change

Previous filing in this sequence was filed on 13 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICVX transaction

Common Stock

Award

Transaction value: $0
Shares: +5,543
Change %: +11%
Price: $0.000000
Shares after: 55,786
Date: 10 Jun 2022
Ownership: Direct
Footnotes: F1

ICVX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,510,228
Date: 10 Jun 2022
Ownership: By Qiming U.S. Healthcare Fund II, L.P.
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICVX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,278
Change %
Price: $0.000000
Shares after: 22,278
Date: 10 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,278
Exercise price: $6.25
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares represent a restricted stock unit ("RSU") award, which shall vest at the earlier of (x) June 10, 2023 or (y) the date of the 2023 Annual Meeting of Stockholders. The vesting of the RSUs is subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the sole general partner of Qiming. The Reporting Person is a managing member of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

Footnote F3

This option vests in substantially equal monthly installments over a twelve-month period commencing on July 10, 2022 (or, in the event the 2023 Annual Meeting of Stockholders occurs prior to June 10, 2023, any remaining unvested portion of the option will vest on the date of the 2023 Annual Meeting of Stockholders), subject to the Reporting Person's continuous service as of the applicable vesting date.